1. Scrip
  2. >>Business
  3. >>Strategy

Novo Nordisk To Target 'New GLP-1 Patients Only' With Weekly Ozempic

 
• By Sten Stovall

Novo Nordisk's head of international operations says trying to switch diabetes patients over to newly approved Ozempic from other GLP-1 medicines is not part of its commercial strategy.

Diabetes
Ozempic Is Newest Once-Weekly GLP-1 Agonist To Reach Market For Type 2 Diabetes • Source: Shutterstock

Novo Nordisk AS will not actively try to get existing diabetes patients who currently use human glucagon-like peptide-1 agonists to swap over to its newly approved once-weekly injectable Ozempic (semaglutide), "because the GLP-1 market is growing, and it's good to have more options, so the main focus will be on capturing new starts," according to the group's international operations chief Maziar Mike Doustdar.

In an interview with Scrip, Doustdar also said the Denmark-based company may have gained a significant edge in a competitive...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

More from Business